Radient Technologies Inc.
Financial Highlights
The balance sheet of the Company remains strong with a cash balance at June 30, 2018 of approximately $17.6 million, up from $9.9 million during the same period in the previous year. The working capital at June 30, 2018 was $17.4 million. Subsequent to the end of the first fiscal quarter, the Company closed equity financing for aggregate gross proceeds of $34.2 million on July 31, 2018 to add to its existing cash position.
The Company believes it has sufficient capital to execute on its strategic partnership with Aurora Cannabis, which includes scaling up its current manufacturing facility and potential expansion in the newly acquired adjacent properties. The Company will be using its proprietary, industrial-scale extraction platform to process cannabinoid extracts from cannabis and hemp while continuing to make investments in infrastructure, technology and expertise that maintain its rigorous standards for quality, yield, and throughput.
With a strengthened balance sheet, the Company is also well positioned to capitalize on opportunities in the European market. To this end, the Company has begun initial development work for a European extraction facility including site selection, preliminary design, and permitting. Furthermore, the Company continues to evaluate strategic partnerships or acquisitions that could increase shareholder value and diversify the Company’s operations, both in the Cannabis and the Health and Wellness segments.
Corporate Update
ACMPR Licence
The Company has submitted its Confirmation of Readiness (“COR”) package to Health Canada to demonstrate its compliance with the ACMPR security requirements. Upon successful completion of the review, the initial ACMPR licence will be granted, which the Company expects to receive prior to October 17, 2018. Upon receipt of the initial ACMPR licence, Radient will be permitted to begin extracting cannabinoids from cannabis biomass at its recently expanded Manufacturing Facility located in Edmonton, Alberta.
Facility Expansion
Radient has completed the expansion of its Manufacturing Facility located at 4035 101 St. in Edmonton, Alberta. Security detailing and other requirements relating to health & safety codes have been accounted for and are now complete. The installation of production equipment as well as related qualification and process validation are scheduled to occur through the remainder of calendar 2018.
Real Estate Expansion
During the first fiscal quarter, the Company closed real estate transactions relating to the Company’s manufacturing facility and adjacent lands in Edmonton Alberta. These acquisitions allow the Company to add significant extraction capacity as may be required by its partners including Aurora Cannabis Inc. which currently has approximately 570,000 kgs of funded cannabis cultivation capacity.
Dealer Licences
The Company received its Dealers Licence from Health Canada’s Office of Controlled substances for its research and development laboratory located at 8223 Roper Road in Edmonton in February 2018. The Company has now submitted its Completion of Construction notification to Health Canada, pertaining to its previous application for a Dealer’s Licence for its Manufacturing Facility located at 4035 101 St. in Edmonton. The Office of Controlled Substances will subsequently schedule an inspection of the facility.
Industrial-scale Nicotine Extraction
During June 2018, the Company completed a submission to the US Food and Drug Administration (FDA) to consider the Company’s unique MAP technology as a method to reduce nicotine levels in tobacco. This followed the Company’s filing of a provisional patent application with the U.S Patent and Trademark Office for innovation related to methods to obtain nicotine depleted tobacco, without altering certain desirable properties of tobacco. The Company will be attending the Global Tobacco and Nicotine Forum in London, UK, September 11-14th, 2018 to meet with leaders in the tobacco industry.
About Radient
Radient extracts natural compounds from a range of biological materials using microwave assisted processing (“MAP™”), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 23,000 square-foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and cannabis markets. Visit www.radientinc.com for more information.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
